Tear film stabilization/ocular surface hydration

"Tear film stabilization/ocular surface hydration" is not a single molecule or receptor but rather a **physiological process** involving multiple molecular components that maintain the health and function of the eye's anterior segment. The **tear film** consists primarily of three layers—lipid, aqueous, and mucin—each produced by different glands/cell types. Key molecular players include membrane-associated mucins such as **MUC1**, **MUC4**, **MUC16**, which are critical for maintaining hydration, lubrication, antiadhesion properties, immune defense functions on the ocular surface epithelium; proteins like lactoferrin and lysozyme provide antimicrobial activity; lipocalin stabilizes lipids in the tear layer; immunoglobulins contribute to immune surveillance[1][2]. Disruption in any component can lead to instability in the tear film ("tear breakup"), increased evaporation or hyperosmolarity—hallmarks seen in dry eye disease. This process is not itself a druggable target but rather an endpoint influenced by therapies aimed at restoring normal secretion/composition/functionality through various mechanisms including anti-inflammatories that reduce cytokine-mediated damage/inflammation; lubricants that supplement deficient layers; secretagogues that stimulate natural production/secretion pathways; agents promoting mucin synthesis for improved wettability/barrier integrity[2][4][6]. Because "Tear film stabilization/ocular surface hydration" refers broadly to a physiological state/process—not a discrete protein/receptor/enzyme—it should not be considered a canonical therapeutic target. > "The most widely studied components...are membrane-associated mucins...which include barrier function regulation...hydration..." [2] > "Dry eye is multifactorial...with cytotoxic inflammatory mediators...altered lacrimal gland secretion...decrease goblet cell density all playing roles..." [4] In summary: this entry describes an important clinical endpoint/process involving many molecules but does not correspond to a single canonical drug target.

Other names

Tear film stabilityOcular surface hydrationTear film homeostasisOcular surface wetting

Supplementation or mimicry of tear components to restore lubrication and barrier function[4][6]; Stimulation of mucin production by goblet cells or epithelial cells[4]; Reduction of inflammation to improve tear film quality and stability[6]